

NRG ONCOLOGY

Advancing Research. Improving Lives.™

NRG Theranostics Subcommittee Institutional Technology Survey / Assessment Update Thomas Ng, MD PhD, Vice Chair

- **NRG Oncology Winter 2026 Meeting in San Francisco**
 - **January 22, 2026**

scng@mgb.org



Needs assessment for clinical trials

Why?

- **Understand the current practice of RPT at NRG sites**
- **Identify challenges and opportunities for promoting RPT trials within NRG**

scng@mgb.org


Needs assessment for clinical trials

How?

- **Pre-survey to identify appropriate contacts at sites**
 - MDs involved with RPT
 - Physics/Technical experts
- **Survey sent to curated list for response, with reminders**
- **2025 Summer/Fall**


Stephen Kry, Cindy Jin, Karan Boparai, Betty O'Meara

RPT is successfully implemented across NRG sites




N = 68


RPT practice distribution is heterogeneous




Access to RPT trial enabling technologies



Current dosimetry capabilities and plans




Current dosimetry capabilities and plans




Current dosimetry capabilities and plans

Top Challenges to Implementing Dosimetry




P < 0.001

Major constraints for RPT trials



How can NRG help?



Notes/comments

- **Infrastructure/support varies across NRG sites (esp. AMC vs. Community)**
 - E.g. implications for designs incorporating dosimetry
- **Costs and competition with clinical work are barriers**
- **Collaboration and consensus across stakeholders at the leadership level important to ensure coordination**

Acknowledgements

- Jeff Michalski, Oliver Sartor, Quynh-Thu Le
- Betty O'Meara, Karan Boparai
- Stephen Kry
- Cindy Jin
- scng@mgb.org – for more details